LEGISLATIVE FISCAL OFFICE
Fiscal Note
Fiscal Note On: SB 63 SLS 202ES 154
Bill Text Version: ORIGINAL
Opp. Chamb. Action:
Proposed Amd.:
Sub. Bill For.:
Date: October 7, 2020 1:11 PM Author: BARROW
Dept./Agy.: Board of Pharmacy
Subject: pharmacist Analyst: Shawn Hotstream
PHARMACISTS OR GF EX See Note Page 1 of 1
Provides for pharmacists to test or screen and initiate therapy for certain health conditions including COVID-19. (See
CA3s19) (Item #40)
Proposed law provides the board of pharmacy to establish a written statewide protocol for pharmacists to test or screen and
initiate treatment or therapy for certain qualified health conditions. The list of qualified conditions for testing, screening, and
treatment or therapy shall include Influenza, Streptococcal infections, COVID-19, HIV, and any other health condition
approved by the board. Treatment or therapy for HIV may include an HIV Pre-Exposure prophylaxis, also known a PrEP, or
an HIV Post-Exposure Prophylaxis, also known as PEP. Proposed law provides that a pharmacist who tests or screens for
and initiates treatment or therapy for a health condition under this measure may use any test that guides diagnosis or
clinical decision making which the Centers for Medicare and Medicaid Services (CMS) has determined qualifies for a waiver in
accordance with the federal Clinical Laboratory Improvement Amendments of 1988 or any established screening procedure
that can safely be performed by a pharmacist under the pharmacist’s professional license.
EXPENDITURES 2020-21 2021-22 2022-23 2023-24 2024-25 5 -YEAR TOTAL
State Gen. Fd. SEE BELOW SEE BELOW SEE BELOW SEE BELOW SEE BELOW
Agy. Self-Gen. INCREASE SEE BELOW SEE BELOW SEE BELOW SEE BELOW
Ded./Other $0 $0 $0 $0 $0 $0
Federal Funds SEE BELOW SEE BELOW SEE BELOW SEE BELOW SEE BELOW
Local Funds $0 $0 $0 $0 $0 $0
Annual Total
REVENUES 2020-21 2021-22 2022-23 2023-24 2024-25 5 -YEAR TOTAL
State Gen. Fd. $0 $0 $0 $0 $0 $0
Agy. Self-Gen. $0 $0 $0 $0 $0 $0
Ded./Other $0 $0 $0 $0 $0 $0
Federal Funds $0 $0 $0 $0 $0 $0
Local Funds $0 $0 $0 $0 $0 $0
Annual Total $0 $0 $0 $0 $0 $0
EXPENDITURE EXPLANATION
The board of pharmacy anticipates a minimal fiscal impact to develop written protocols for pharmacists for their use in the
testing/screening for certain health conditions as well as their initiation of treatment or therapy for those health conditions.
Costs are associated with board member per diem and travel ($2,000) to meet with various pharmacy practitioners and
medical consultants to develop protocols. The Louisiana Department of Health indicates no anticipated costs associated with
proposed legislation. Note: The LFO has asked the department if a pharmacist providing screening, testing, and initiation of
treatment under this measure would be considered billable services for Medicaid eligibles.
REVENUE EXPLANATION
There is no anticipated direct material effect on governmental revenues as a result of this measure.
Senate Dual Referral Rules House
13.5.1 >= $100,000 Annual Fiscal Cost {S & H} 6.8(F)(1) >= $100,000 SGF Fiscal Cost {H & S}
Christopher A. Keaton
13.5.2 >= $500,000 Annual Tax or Fee 6.8(G) >= $500,000 Tax or Fee Increase
Change {S & H} or a Net Fee Decrease {S} Legislative Fiscal Officer